Allopurinol prescribing for gout management in Aotearoa New Zealand

Phase 4

Recruiting

• Conditions: Gout; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12622001279718
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-29
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 380

Inclusion Criteria

1. Age over 18 years
2. Gout according to the 2015 ACR/EULAR criteria
3. Serum urate greater than or equal to 0.36mmol/l (6mg/dl) AND
-not taking allopurinol, but starting urate-lowering therapy strongly recommended in the 2020 ACR gout management guidelines (i.e. any of the following: greater than or equal to 2 gout flares/year, greater than or equal to 1 subcutaneous tophi, radiographic damage due to gout) OR
-already taking allopurinol for gout at lower than predicted dose OR
-already taking allopurinol but not regularly
4. Agreeable to starting or continuing allopurinol
5. Ability to give informed consent
6. Ability to communicate via telephone

Exclusion Criteria

1. Severe kidney disease with estimated glomerular filtration rate (eGFR) <30ml/min/1.73m2
2. Contra-indication or previous intolerance to allopurinol
3. Concomitant azathioprine, due to interactions with allopurinol
4. HLA-B*5801 positive in high allele frequency populations (South East Asian and African), due to high risk of allopurinol hypersensitivity syndrome
5. Female of childbearing age not on contraception
5. Unstable co-morbid health conditions (e.g. NYHA stage 4 heart failure, recent myocardial infarction, advanced cancer)
6. Dementia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of participants with serum urate <0.36mmol/l[ Month 12 post-intervention commencement]